Windtree Therapeutics, a Nasdaq-listed biotech firm, announced plans to buy up to $700 million worth of BNB after the cryptocurrency hit a new all-time high. The company is raising $520 million specifically for BNB purchases following a prior commitment of $200 million. They have established a strategic partnership with Kraken for custody services related to their BNB Crypto Treasury Strategy. CEO Jed Latkin emphasized that acquiring additional funds is crucial for their strategy, pending stockholder approval. Currently, BNB holds the position as the fifth-largest digital coin and has a market cap of approximately $106.9 billion. While Windtree's stock has seen a decline of about 5% recently, it has risen significantly by 162% over the past month. This move aligns with a growing trend among publicly traded companies to establish crypto treasuries as a means to enhance their financial strategies.

Source šŸ”—